![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/menarini-anuncia-datos-positivos-del-ensayo-clinico-fundamental-de-fase-3-brooklyn-302209004.html
https://www.prnewswire.com/news-releases/menarinis-cell-based-non-invasive-prenatal-technology-demonstrates-high-resolution-detection-of-fetal-genomic-abnormalities-from-a-simple-maternal-blood-draw-302187230.html
https://www.biospectrumasia.com/news/30/23964/docquity-enables-italian-biopharma-company-menarini-to-double-healthcare-engagement-in-malaysia.html
https://www.prnewswire.com/news-releases/menarini-group-presented-initial-safety-and-efficacy-data-from-phase-1b2-elevate-and-electra-combination-studies-of-orserdu-elacestrant-in-patients-with-er-her2--metastatic-breast-cancer-mbc-at-the-2023-san-antonio-breast--302011539.html
https://www.prnewswire.com/news-releases/menarini-group-announces-new-data-on-orserdu-elacestrant-at-the-2023-san-antonio-breast-cancer-symposium-and-on-elzonris-tagraxofusp-erzs-at-the-65th-american-society-of-hematology-annual-meeting-and-exposition-301994634.html